• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[原抗精神病药物二乙嗪在动物和人体中的药代动力学特征]

[Specific features in pharmacokinetics of the original neuroleptic dilept in animals and humans].

作者信息

Shevchenko R V, Litvin A A, Kolyvanov G B, Boĭko S S, Zherdev V P

出版信息

Eksp Klin Farmakol. 2014;77(7):23-6.

PMID:25322650
Abstract

Interspecies differences in pharmacokinetics of the original neuroleptic drug dilept have been studied in experimental animals (rabbits and rats) and volunteers after single oral administration of tablets and tablet mass of the drug. Parent drug in the rabbit blood plasma was detected for 4 h, in the rat plasma for about 2 h, and in the human blood plasma for about 1 h after drug administration. The degrees of dilept biotransformation into metabolites (defined as metabolism intensity, AUCM/AUCP) in rats were 21.3 (for M-1) and 1645 (for M-2), in human volunteers - 5.8 and 658.5, and in rabbits - 1.6 and 125.8, respectively. Thus, the intensity of drug metabolism in experimental animals and volunteers was different and decreased in the series rats humans rabbits.

摘要

在实验动物(兔子和大鼠)及志愿者单次口服原抗精神病药物二联苯哌啶片剂和片剂制剂后,对其药代动力学的种间差异进行了研究。给药后,在兔血浆中可检测到母体药物4小时,在大鼠血浆中约为2小时,在人血浆中约为1小时。二联苯哌啶转化为代谢产物的程度(定义为代谢强度,AUCM/AUCP)在大鼠中,M-1为21.3,M-2为1645;在人类志愿者中分别为5.8和658.5;在兔子中分别为1.6和125.8。因此,实验动物和志愿者体内药物代谢强度不同,且按大鼠、人类、兔子的顺序递减。

相似文献

1
[Specific features in pharmacokinetics of the original neuroleptic dilept in animals and humans].[原抗精神病药物二乙嗪在动物和人体中的药代动力学特征]
Eksp Klin Farmakol. 2014;77(7):23-6.
2
[Clinic pharmacokinetics of a new original antipsychotic drug Dilept].新型原创抗精神病药物Dilept的临床药代动力学
Eksp Klin Farmakol. 2013;76(6):34-7.
3
[Experimental pharmacokinetics of the new neurotensine-derived antipsychotic drug dilept].[新型神经降压素衍生抗精神病药物二氯嗪的实验药代动力学]
Eksp Klin Farmakol. 2009 May-Jun;72(3):16-21.
4
Comparison of pharmacokinetics and relative bioavailability of tablets and substance of new dipeptide neuroleptic dilept.新型二肽神经阻滞剂双氯芬酸片剂与原料药的药代动力学及相对生物利用度比较。
Bull Exp Biol Med. 2014 Oct;157(6):735-7. doi: 10.1007/s10517-014-2655-1. Epub 2014 Oct 29.
5
[Dilept: a tripeptoid neurotensin analog combining neuroleptic activity with positive mnemotropic action].
Eksp Klin Farmakol. 2005 Jan-Feb;68(1):3-6.
6
[Neurotensine dipeptide analog dilept decreases the deficiency of prestimulus startle reflex inhibition: a prognostic sign of antipsychotic activity].
Eksp Klin Farmakol. 2009 Sep-Oct;72(5):3-7.
7
[The new tripeptoid neurotensin analog dilept selectively affects dopamine turnover in nucleus accumbens and hypothalamus].新型三肽类神经降压素类似物双轻肽选择性影响伏隔核和下丘脑的多巴胺代谢
Eksp Klin Farmakol. 2005 Nov-Dec;68(6):15-8.
8
Permeability of the blood-brain barrier for dilept and its active metabolite.双丙戊酸钠及其活性代谢物的血脑屏障通透性。
Bull Exp Biol Med. 2011 Jul;151(3):330-2. doi: 10.1007/s10517-011-1322-z.
9
[Decrease in the glutamate release may contribute to the neuroprotective action of the novel neuroleptic drug dilept].
Eksp Klin Farmakol. 2007 May-Jun;70(3):3-5.
10
[The search of small molecules with antipsychotic activity on the background of neurotensin].
Bioorg Khim. 2012 Jan-Feb;38(1):119-26.